delta-9-tetrahydrocannabinol/cannabidiol (TN-TC11G)
/ Tilray
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
October 04, 2024
GEINOCANN: TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma
(clinicaltrials.gov)
- P1/2 | N=33 | Active, not recruiting | Sponsor: Grupo Español de Investigación en Neurooncología | Recruiting ➔ Active, not recruiting
Enrollment closed • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor
September 18, 2023
GEINOCANN: TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma
(clinicaltrials.gov)
- P1/2 | N=30 | Recruiting | Sponsor: Grupo Español de Investigación en Neurooncología | Not yet recruiting ➔ Recruiting
Enrollment open • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor • MDK
February 23, 2023
GEINOCANN: TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma
(clinicaltrials.gov)
- P1/2 | N=30 | Not yet recruiting | Sponsor: Grupo Español de Investigación en Neurooncología | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Mar 2024 ➔ Mar 2025
Trial completion date • Trial primary completion date • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor • MDK
August 03, 2022
GEINOCANN: TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma
(clinicaltrials.gov)
- P1/2 | N=30 | Not yet recruiting | Sponsor: Grupo Español de Investigación en Neurooncología | Trial completion date: Dec 2023 ➔ Dec 2024 | Trial primary completion date: Sep 2023 ➔ Mar 2024
Trial completion date • Trial primary completion date • Brain Cancer • Glioblastoma • Oncology • Solid Tumor • MDK
1 to 4
Of
4
Go to page
1